Scynexis (SCYX) Reports First Patient Dosed in Phase 3 Open-Label Study Evaluating Oral Ibrexafungerp in Candida auris Infections
Tweet Send to a Friend
SCYNEXIS, Inc. (NASDAQ: SCYX) today announced the dosing of the first patient with a Candida auris infection, an emerging ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
